Navigating the latest biotech funding surge

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 April 30, 2024 Navigating the latest biotech funding surge Good morning, 360! Don’t forget to join us today for LIVE trading in the [Market Master’s Room](. We’ll talk about today’s Spotlight Stock and all things Market! FOCUS LIST🔎 CYCC - Up over 50% in pre after announcing $8.0 million private placement WGS - Up over 20% in pre after reporting 96% Q1 24 year-over-year revenue growth DARE - Up over 25% in pre after announcing $22 million in non-dilutive strategic royalty financing to advance Phase 3 women’s health product *sponsored by Cardiol Therapeutics Today’s Spotlight stock is Cardiol Therapeutics Inc. (CRDL) – a clinical-stage life sciences company developing cannabidiol-based products to treat heart diseases. You can see the overwhelming bullish trend for the stock by looking at CRDL’s chart showing its daily action for nearly a year The two highlighted areas on the chart above show a “wedge pattern.” Those are times when the trading range becomes extremely tight, and it is usually followed by a significant move. When you have a rising wedge (like we see above), the breakout to the upside can be significant. These moves can happen very quickly, so it is important to prepare and have a plan in place. If you see the last time CRDL broke out of this wedge, it gained over 50% in just a few days. You will be hard-pressed to find a stock with the remarkable strength that we have seen for CRDL over the last several months. Even with all of the market “chop,” CRDL has managed to more than double its price so far this year. So make sure you are keeping a close eye on CRDL. Do your own research if you decide to trade it and have a plan in place that you stick to ([for our full report, click here](). Trading is very risky, and nothing is guaranteed, so never trade with more than you can afford to lose. *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 CYCC - Up over 50% in pre after announcing $8.0 million private placement Cyclacel Pharmaceuticals Inc. (CYCC) is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer and other proliferative diseases in the United States and internationally. In the after-hours yesterday, the [company announced]( it had entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $8.0 million/ The stock traded up over 50% in the pre-market in response to the news. The $1.94 area acted as support in the after hours and pre-market and will be an important level to watch. Above it, targets to the upside are $2.20, $2.40, $2.50, $2.70 and then the pre-market high at $2.75. Beyond that, $3 and $4 come into play. Below $1.94, targets to the downside are $1.70, $1.50 and then a gap fill at $1.36. WGS - Up over 20% in pre after reporting 96% Q1 24 year-over-year revenue growth GeneDx Holdings Corp. (WGS) provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. In the after-hours yesterday, the [company reported]( Q1 24 earnings. Highlights include: Q1 2024 revenue from continuing operations of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025. The stock traded up over 20% in the pre-market in reaction to the earnings report. The $13.45 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $13.90, $14.25, $15, $15.40 and then the pre-market high $15.89. Beyond that, $16.10 and $17.10 come into play. Below $13.45, targets to the downside are $13.10, $12.50, $12 and then a gap fill at $11. IBRX for the Cheddar Drop JW hunts down the juiciest swing trades with his custom scanner and AI-enabled “Go, No Go!” signals. [Up your trading game with Atomic Trades today!]( DARE - Up over 25% in pre after announcing $22 million in non-dilutive strategic royalty financing to advance Phase 3 women’s health product Daré Bioscience, Inc. (DARE) is a biopharmaceutical company that identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. In the pre-market this morning, the [company announced]( that it had closed a royalty monetization transaction with XOMA (US) LLC. DARE received $22 million in gross proceeds at close and, following a pre-specified total return to XOMA, XOMA will make upside-sharing milestone payments to Daré equal to 50% of all remaining cash flows sold to XOMA under the transaction. The $22 million of non-dilutive capital at close provides significant capital to achieve objectives. The transaction allows DARE to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential first FDA-approved treatment for female sexual arousal disorder through key catalysts Previously announced royalty financing remains outstanding, bringing royalty-based capital committed to $34 million. The stock traded up over 25% in the pre-market after the news. The $0.32 area acted as support in the pre-market and now becomes a potential resistance level. Above it, targets to the upside are $0.33, $0.34, $0.3675 and then the pre-market high at $0.39. Beyond that, $0.45 and $0.50 come into play. Below $0.32, targets to the downside are $0.31, $0.30 and then a gap fill at $0.2819. MARKET NEWS 📰 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull *ISSUER-PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars directly from Cardiol Therapeutics Inc. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Cardiol Therapeutics Inc, increased trading volume, and possibly an increased share price of Cardiol Therapeutics Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Cardiol Therapeutics Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America